X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BPL-003 (mebufotenin) is Beckley Psytech’s novel, synthetic, patent-protected benzoate salt formulation of 5-MeO-DMT (mebufotenin) and is administered intranasally. It is being evaluated for the treatment of treatment resistant depression.
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Product Name: BPL-003
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2024
Details:
BPL-003, a novel synthetic formulation of 5-MeO-DMT (also known as mebufotenin), which is investigated for the treatment of treatment Resistant Depression (TRD).
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Product Name: BPL-003
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2023
Details:
BPL-003 (mebufotenin) is a psychoactive indolealkylamine derivative of tryptamine and binds to a variety of serotonergic 5-HT receptors which is considered to be the mechanism for its psychoactive effects.
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Product Name: BPL-003
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2023
Details:
BPL-003 (mebufotenin) is a psychoactive indolealkylamine derivative of tryptamine and binds to a variety of serotonergic 5-HT receptors which is considered to be the mechanism for its psychoactive effects.
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Product Name: BPL-003
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2023
Details:
BPL-003 (mebufotenin) is a psychoactive indolealkylamine derivative of tryptamine and binds to a variety of serotonergic 5-HT receptors which is considered to be the mechanism for its psychoactive effects.
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Product Name: BPL-003
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2023
Details:
BPL-003, a proprietary intranasal formulation of synthetic 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT), for Treatment Resistant Depression. Phase I study earlier this year, showed that BPL-003 was well tolerated and pharmacokinetics and shortlasting pharmacodynamic effects.
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Product Name: BPL-003
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2022
Details:
BPL-003, a synthetic intranasal formulation of 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT), which is under development for Treatment Resistant Depression and Alcohol Use Disorder.
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Product Name: BPL-003
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2022
Details:
ELE-101, a novel, short-acting psychedelic compound which is intended to serve as a possible treatment for depression. ELE-101 was added to Beckley Psytech’s portfolio following the acquisition of Eleusis Therapeutics Limited in October 2022.
Lead Product(s): Psilocin
Therapeutic Area: Psychiatry/Psychology Product Name: ELE-101
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2022
Details:
The acquisition adds ELE-101, a next-generation, short-duration psychedelic ready for Phase 1 clinical trials, to Beckley Psytech’s pipeline. ELE-101 is an intravenous (IV) formulation of psilocin, the active metabolite of psilocybin.
Lead Product(s): Psilocin
Therapeutic Area: Psychiatry/Psychology Product Name: ELE-101
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Eleusis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 24, 2022
Details:
By partnering with Ksana Health, Beckley Psytech aims to track novel, predictive digital biomarkers to follow patient progress in upcoming Phase 2 evaluating the use of 5-MeO-DMT (BPL-003) in combination with psychotherapy in the treatment of treatment resistant depression.
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Product Name: BPL-003
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ksana Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 14, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
